Glucagon-Like Peptide-1 Receptor Agonists and Pancreatic Cancer Risk in Patients with Type 2 Diabetes

Pancreatic cancer incidence was compared according to weighted cumulative exposures to glucagon-like peptide-1 receptor agonists and to basal insulin in a Cox model implemented in discrete time, with time origin at two years after diabetes diagnosis, adjusting for confounding.